Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Leukemia. 2014 Jul 18. pii: leu2014217. doi: 10.1038/leu.2014.217. pmc: PMC4320294
    A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR.
    White H1,  Deprez L2,  Corbisier P3,  Hall V4,  Lin F5,  Mazoua S6,  Trapmann S7,  Aggerholm A8,  Andrikovics H9,  Akiki S10,  Barbany G11,  Boeckx N12,  Bench A13,  Catherwood M14,  Cayuela JM15,  Chudleigh S16,  Clench T17,  Colomer D18,  Daraio F19,  Dulucq S20,  Farrugia J21,  Fletcher L22,  Foroni L23,  Ganderton R24,  Gerrard G25,  Gineikienė E26,  Hayette S27,  El Housni H28,  Izzo B29,  Jansson M30,  Johnels P31,  Jurcek T32,  Kairisto V33,  Kizilors A34,  Kim DW35,  Lange T36,  Lion T37,  Polakova KM38,  Martinelli G39,  McCarron S40,  Merle PA41,  Milner B42,  Mitterbauer-Hohendanner G43,  Nagar M44,  Nickless G45,  Nomdedéu J46,  Nymoen DA47,  Leibundgut EO48,  Ozbek U49,  Pajič T50,  Pfeifer H51,  Preudhomme C52,  Raudsepp K53,  Romeo G54,  Sacha T55,  Talmaci R56,  Touloumenidou T57,  Van der Velden VH58,  Waits P59,  Wang L60,  Wilkinson E61,  Wilson G62,  Wren D63,  Zadro R64,  Ziermann J65,  Zoi K66,  Müller MC67,  Hochhaus A68,  Schimmel H69,  Cross NC70,  Emons H71
    Author information
    11] National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Salisbury, UK [2] Faculty of Medicine, University of Southampton, Southampton, UK.
    2European Commission, Joint Research Centre, Institute for Reference Materials and Measurements, Geel, Belgium.
    3European Commission, Joint Research Centre, Institute for Reference Materials and Measurements, Geel, Belgium.
    4National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Salisbury, UK.
    51] National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Salisbury, UK [2] Faculty of Medicine, University of Southampton, Southampton, UK.
    6European Commission, Joint Research Centre, Institute for Reference Materials and Measurements, Geel, Belgium.
    7European Commission, Joint Research Centre, Institute for Reference Materials and Measurements, Geel, Belgium.
    8Department of Haematology, Aarhus University Hospital, Aarhus, Denmark.
    9Hungarian National Blood Transfusion Service, Budapest, Hungary.
    10Regional Genetics Laboratory, Birmingham Women's NHS Foundation Trust, Birmingham, UK.
    11Department of Molecular Medicine and Surgery, Clinical Genetics Karolinska Institutet, Stockholm, Sweden.
    121] Department of Laboratory Medicine, UZ Leuven, Belgium [2] Department of Oncology, KU Leuven, Belgium.
    13Molecular Malignancy Laboratory and Haemato-Oncology Diagnostic Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
    14Haematology Department, Belfast City Hospital, Belfast, UK.
    15Haematology Laboratory and EA3518, University Hospital Saint-Louis, AP-HP, University Paris Diderot, Paris, France.
    16Department of Molecular Haematology, Yorkhill NHS Trust, Glasgow, UK.
    17Molecular Haematology, Bristol Royal Infirmary, Bristol, UK.
    18Hematopathology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain.
    19Department of Clinical and Biological Science, University of Turin, Turin, Italy.
    20Laboratoire Hematologie, CHU Bordeaux, Hematopoiese Leucemique et Cibles Therapeutiques, INSERM U1035, Universite Bordeaux, Bordeaux, France.
    21Combined Laboratories, Derriford Hospital, Plymouth, UK.
    22Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia.
    23Imperial Molecular Pathology, Centre for Haematology, Imperial College London, London, UK.
    24Molecular Pathology, University Hospitals Southampton NHS Foundation Trust, Southampton, UK.
    25Imperial Molecular Pathology, Centre for Haematology, Imperial College London, London, UK.
    26Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania.
    27Laboratory of Molecular Biology and UMR5239, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite, France.
    28Medical Genetics Department, Erasme Hospital, Brussels, Belgium.
    29Department of Clinical Medicine and Surgery, University 'Federico II' of Naples, Naples, Italy.
    30Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
    31Department of Clinical Genetics, University and Regional Laboratories, Lund, Sweden.
    32Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
    33Turku University Hospital, TYKSLAB, Laboratory of Molecular Genetics, Turku, Finland.
    34Laboratory for Molecular Haemato-Oncology, Kings College Hospital, London, UK.
    35Cancer Research Institute, The Catholic University of Korea, Seoul, South Korea.
    36Abteilung für Hämatologie und internistische Onkologie, Universität Leipzig, Leipzig, Germany.
    37Children's Cancer Research Institute/LabDia Labordiagnostik and Medical University, Vienna, Austria.
    38Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
    39Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
    40Cancer Molecular Diagnostics, St James's Hospital, Dublin, Ireland.
    41VU Medical Centre, Department of Haematology, Amsterdam, The Netherlands.
    42Department of Medical Genetics, NHS-Grampian, Aberdeen, UK.
    43Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
    44Laboratory of Hematology, Sheba Medical Center, Tel Hashomer, Israel.
    45Molecular Oncology Diagnostics Unit, Guy's Hospital, London, UK.
    46Lab Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
    47Division of Pathology, Rikshospital, Oslo University Hospital, Oslo, Norway.
    48Molecular Diagnostics Laboratory, Department of Hematology, University Hospital Bern, Bern, Switzerland.
    49Genetics Department, Institute of Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey.
    50Specialized Haematology Laboratory, Division of Internal Medicine, Department of Haematology, University Medical Centre, Ljubljana, Slovenia.
    51Department of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt, Germany.
    52Laboratoire d'hématologie, CHU Lille, Lille, France.
    53United Laboratories of Tartu University Hospitals, Tartu, Estonia.
    54Molecular Haematology Laboratory, PathWest Laboratory Medicine, Royal Perth Hospital, Perth, WA, Australia.
    55Hematology Department, Jagiellonian University, Krakow, Poland.
    56Hematology Department, Fundeni Clinical Institute, University of Medicine and Pharmacy 'Carol Davila', Bucharest, Romania.
    57Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
    58Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.
    59Bristol Genetics Laboratory, Southmead Hospital, Bristol, UK.
    60Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK.
    61HMDS, Leeds Institute of Oncology, St James's University Hospital, Leeds, UK.
    62Sheffield Diagnostic Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK.
    63Molecular Diagnostics, The Royal Marsden NHS Foundation Trust, Sutton, UK.
    64Department of Laboratory Diagnostics, Clinical Hospital Center, Zagreb University School of Medicine, Zagreb, Croatia.
    65Department of Hematology/Oncology, Jena University Hospital, Jena, Germany.
    66Haematology Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece.
    67III. Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany.
    68Department of Hematology/Oncology, Jena University Hospital, Jena, Germany.
    69European Commission, Joint Research Centre, Institute for Reference Materials and Measurements, Geel, Belgium.
    701] National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Salisbury, UK [2] Faculty of Medicine, University of Southampton, Southampton, UK.
    71European Commission, Joint Research Centre, Institute for Reference Materials and Measurements, Geel, Belgium.
    Abstract

    Serial quantification of BCR-ABL1 mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there is a substantial variation in results reported by different laboratories. To improve comparability, an internationally accepted plasmid certified reference material (CRM) was developed according to ISO Guide 34:2009. Fragments of BCR-ABL1 (e14a2 mRNA fusion), BCR and GUSB transcripts were amplified and cloned into pUC18 to yield plasmid pIRMM0099. Six different linearised plasmid solutions were produced with the following copy number concentrations, assigned by digital PCR, and expanded uncertainties: 1.08±0.13 × 10(6), 1.08±0.11 × 10(5), 1.03±0.10 × 10(4), 1.02±0.09 × 10(3), 1.04±0.10 × 10(2) and 10.0±1.5 copies/μl. The certification of the material for the number of specific DNA fragments per plasmid, copy number concentration of the plasmid solutions and the assessment of inter-unit heterogeneity and stability were performed according to ISO Guide 35:2006. Two suitability studies performed by 63 BCR-ABL1 testing laboratories demonstrated that this set of 6 plasmid CRMs can help to standardise a number of measured transcripts of e14a2 BCR-ABL1 and three control genes (ABL1, BCR and GUSB). The set of six plasmid CRMs is distributed worldwide by the Institute for Reference Materials and Measurements (Belgium) and its authorised distributors (https://ec.europa.eu/jrc/en/reference-materials/catalogue/; CRM code ERM-AD623a-f).


    Publikations ID: 25036192
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt